Vidac Pharma Secures EUR 20m Capital Commitment From GEM
CET- Comunicado - ";ultimaHoraHtml += " " + json.lead + "";}ultimaHoraHtml += ""; document.getElementById("urgente").innerHTML = ultimaHoraHtml; } } }); NESS-ZIONA, Israel, April 19, 2021 /PRNewswire/ -- Vidac Pharma LTD (Vidac) a clinical-stage Israel biopharmaceutical company, announced today that it has signed an agreement with GEM Global Yield LLC SCS ("GEM") a Luxemburg-based private alternative investment group for a EUR 20 million capital commitment. Under the agreement, GEM commits to provide Vidac with a share subscription facility of up to EUR...